The Incentive Bias: Subject Underreporting of Adverse Drug Effects
DOI:
https://doi.org/10.15173/m.v1i27.961Abstract
I discuss my experience participating in a clinical trial and my encounters with other subjects. Through this unique position I gained the perspective of the typical study participant, which led to the discovery of fears which deter subjects from reporting symptoms. This incentive bias is caused by the financial duress of many participants, resulting in a high incentive to complete the study. Changes in health go unreported reported which skews adverse drug reaction data and leads to additional costs imposed to healthcare. Clinical trials should strive to eliminate incentive bias to improve the transparency and increase reporting fidelity.
References
Bent S, Padula A, Avins AL. Better ways to question patients about adverse medical events. Ann. Intern. Med. 144, 257-261 (2006).
Martin RM, Kapoor KV, Wilton LV, Mann RD. Under-reporting of suspected adverse drug reactions to newly marketed ('black triangle') drugs in general practice: observational study. BMJ 317, 119-120 (1998).
Ioannidis JP, Evans SJ, Gotzsche PC, O’Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 141:781-8 (2004).
U.S. Food and Drug Administration. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (1995)
